Philipp Zickler

Dr. Philipp Zickler

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
GWGil I Wolfe
Gil I Wolfe
HKHenry J Kaminski
Henry J Kaminski
IAInmaculada B Aban
Inmaculada B Aban
GMGreg Minisman
Greg Minisman
HKHui-Chien Kuo
Hui-Chien Kuo
NGNina Gorham
Nina Gorham

21 June 2002 in Blood
Verified
Journal Article
Open access
PDF file
MSManfred Schmidt
Manfred Schmidt
PZPhilipp Zickler
Philipp Zickler
GHGesa Hoffmann
Gesa Hoffmann
SHSebastian Haas
Sebastian Haas
MWManuela Wissler
Manuela Wissler
CKChristof von Kalle
Christof von Kalle
Hematopoietic bone marrow stem cells generate differentiated blood cells and, when transplanted, may contribute to other organs, such as the brain, heart, and l

13 April 2006 in Brain
Verified
Journal Article
Closed access
PDF file
MSMichael Schroeter
Michael Schroeter
PZPhilipp Zickler
Philipp Zickler
DDDavid T. Denhardt
David T. Denhardt
HHHans-Peter Hartung
Hans-Peter Hartung
SJSebastian Jander
Sebastian Jander
Inflammation aggravates brain injury caused by stroke and neurodegeneration. Osteopontin (OPN) is a cytokine-like glycoprotein that binds to various integrins and CD44 variants. OPN exerts proinflammatory effects in autoimmune conditions but also has cytoprotective properties and participates in wound healing. In this study, we addressed the role of OPN in ischaemic brain injury using OPN knock-out (KO) mice in models of cortical stroke. Compared with wild-type animals, OPN KO mice exhibited unaltered infarct development at the primary injury site but greatly increased retrograde degeneration of the ipsilateral thalamus. Thalamic neurodegeneration in OPN-deficient mice was associated with pronounced microglia activation and inflammatory gene expression and could be attenuated via pharmacological blockade of the inducible nitric oxide synthase (iNOS). Therefore, delayed neurodegeneration in OPN-deficient mice was at least partly due to an excessive release of nitric oxide via the iNOS pathway. Neuroprotective and anti-inflammatory effects of OPN may be relevant for a variety of neurological disease conditions.

1 June 2005 in Experimental Hematology
Verified
Journal Article
Closed access
EKElizabeth M. Kang
Elizabeth M. Kang
PZPhilipp Zickler
Philipp Zickler
SBSean Burns
Sean Burns
SLSaskia M. Langemeijer
Saskia M. Langemeijer
SBSebastian Brenner
Sebastian Brenner
JTJohn F. Tisdale
John F. Tisdale

2 June 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DKDavid Kremer
David Kremer
AHAndré Heinen
André Heinen
JJJanusz Jadasz
Janusz Jadasz
PGPeter Göttle
Peter Göttle
KZKristin Zimmermann
Kristin Zimmermann
Patrick KueryPatrick Kuery
Patrick Kuery
The mechanisms preventing efficient remyelination in the adult mammalian central nervous system after demyelinating inflammatory diseases, such as multiple sclerosis, are largely unknown. Partial remyelination occurs in early disease stages, but repair capacity diminishes over time and with disease progression. We describe a potent candidate for the negative regulation of oligodendroglial differentiation that may underlie failure to remyelinate. The p57kip2 gene is dynamically regulated in the spinal cord during MOG-induced experimental autoimmune encephalomyelitis. Transient down-regulation indicated that it is a negative regulator of post-mitotic oligodendroglial differentiation. We then applied short hairpin RNA-mediated gene suppression to cultured oligodendroglial precursor cells and demonstrated that down-regulation of p57kip2 accelerates morphological maturation and promotes myelin expression. We also provide evidence that p57kip2 interacts with LIMK-1, implying that p57kip2 affects cytoskeletal dynamics during oligodendroglial maturation. These data suggest that sustained down-regulation of p57kip2 is important for oligodendroglial maturation and open perspectives for future therapeutic approaches to overcome the endogenous remyelination blockade in multiple sclerosis.

6 February 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
CMC.J. Maurer
C.J. Maurer
TDT. Dobrocky
T. Dobrocky
FJF. Joachimski
F. Joachimski
UNU. Neuberger
U. Neuberger
TDT. Demerath
T. Demerath
Sebastian FischerSebastian Fischer
Sebastian Fischer
BACKGROUND AND PURPOSE: Large intracranial vessel occlusion due to calcified emboli is a rare cause of major stroke. We assessed the prevalence, imaging appearance, the effectiveness of mechanical thrombectomy, and clinical outcome of patients with large-vessel occlusion due to calcified emboli. MATERIALS AND METHODS: We performed a retrospective analysis of clinical and procedural data of consecutive patients who underwent mechanical thrombectomy due to calcified emboli in 7 European stroke centers. RESULTS: We screened 2969 patients, and 40 patients matched the inclusion criteria, accounting for a prevalence of 1.3%. The mean maximal density of the thrombus was 327 HU (range, 150–1200 HU), and the mean thrombus length was 9.2 mm (range, 4–20 mm). Four patients had multiple calcified emboli, and 2 patients had an embolic event during an endovascular intervention. A modified TICI score of ≥2b was achieved in 57.5% (23/40), with minimal-to-no reperfusion (modified TICI 0–1) in 32.5% (13/40) and incomplete reperfusion (modified TICI 2a) in 10% (4/40). Excellent outcome (mRS 0–1) was achieved in only 20.6%, functional independence (mRS 0–2) in 26.5% and 90-day mortality was 55.9%. CONCLUSIONS: Acute ischemic stroke with large-vessel occlusion due to calcified emboli is a rare entity in patients undergoing thrombectomy, with considerably worse angiographic outcome and a higher mortality compared with patients with noncalcified thrombi. Good functional recovery at 3 months can still be achieved in about a quarter of patients.